Literature DB >> 25350518

Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium.

I Kourtzelis1, A Ferreira1, I Mitroulis1, D Ricklin2, S R Bornstein3, C Waskow4, J D Lambris2, T Chavakis1.   

Abstract

Xenotransplantation (xeno-Tx) is considered as an alternative solution to overcome the shortage of human donor organs. However, the success of xeno-Tx is hindered by immune reactions against xenogeneic cells (e. g. of porcine origin). More specifically, activation of innate immune mechanisms such as complement and triggering of the coagulation cascade occur shortly after xeno-Tx, and adhesion of human leukocytes to porcine endothelium is another early critical step mediating the immune attack. To investigate the therapeutic potential of complement inhibition in the context of xenogeneic interactions, we have employed a whole-blood model in the present study. Incubation of human blood with porcine endothelial cells (PAECs) led to activation of complement and coagulation as well as to increased leukocyte adhesion. The observed responses can be attributed to the pig-to-human xenogeneicity, since the presence of human endothelium induced a minor cellular and plasmatic inflammatory response. Importantly, complement inhibition using a potent complement C3 inhibitor, compstatin analogue Cp40, abrogated the adhesion of leukocytes and, more specifically, the attachment of neutrophils to porcine endothelium. Moreover, Cp40 inhibited the activation of PAECs and leukocytes, since the levels of the adhesion molecules E-selectin, ICAM-1, ICAM-2, and VCAM-1 on PAECs and the surface expression of integrin CD11b on neutrophils were significantly decreased. Along the same line, inhibition of CD11b resulted in decreased leukocyte adhesion. Taken together, our findings provide a better understanding of the mechanisms regulating the acute innate immune complications in the context of xeno-Tx and could pave the way for complement-targeting therapeutic interventions. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25350518      PMCID: PMC4383746          DOI: 10.1055/s-0034-1390452

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  56 in total

1.  Role of porcine P-selectin in complement-dependent adhesion of human leukocytes to porcine endothelial cells.

Authors:  S A Rollins; K K Johnson; L Li; C Birks; L A Matis; R P Rother
Journal:  Transplantation       Date:  2000-04-27       Impact factor: 4.939

2.  The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium: implications for xenotransplantation.

Authors:  L A Robinson; L Tu; D A Steeber; O Preis; J L Platt; T F Tedder
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.

Authors:  B Nilsson; R Larsson; J Hong; G Elgue; K N Ekdahl; A Sahu; J D Lambris
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

Review 4.  Depletion of natural antibodies in non-human primates--a step towards successful discordant xenografting in humans.

Authors:  D K Cooper
Journal:  Clin Transplant       Date:  1992-06       Impact factor: 2.863

5.  Expression and function of C5a receptor in mouse microvascular endothelial cells.

Authors:  Ines J Laudes; Jeffrey C Chu; Markus Huber-Lang; Ren-Feng Guo; Niels C Riedemann; J Vidya Sarma; Fakhri Mahdi; Hedwig S Murphy; Cecilia Speyer; Kristina T Lu; John D Lambris; Firas S Zetoune; Peter A Ward
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Reaction of complement with endothelial cells in a model of xenotransplantation.

Authors:  A P Dalmasso; J L Platt; F H Bach
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

7.  Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.

Authors:  A P Dalmasso; G M Vercellotti; J L Platt; F H Bach
Journal:  Transplantation       Date:  1991-09       Impact factor: 4.939

8.  Adherence of human monocytes and NK cells to human TNF-alpha-stimulated porcine endothelial cells.

Authors:  X F Zhang; M F Feng
Journal:  Immunol Cell Biol       Date:  2000-12       Impact factor: 5.126

9.  C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.

Authors:  S Miyagawa; S Mikata; R Shirakura; H Matsuda; S Nagasawa; A Terados; M Hatanaka; M Matsumoto; T Seya
Journal:  Scand J Immunol       Date:  1996-04       Impact factor: 3.487

10.  Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor.

Authors:  A P Dalmasso; J L Platt
Journal:  Transplantation       Date:  1993-11       Impact factor: 4.939

View more
  11 in total

Review 1.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

Review 2.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 3.  The complex functioning of the complement system in xenotransplantation.

Authors:  Hongmin Zhou; Hidetaka Hara; David K C Cooper
Journal:  Xenotransplantation       Date:  2019-04-29       Impact factor: 3.907

Review 4.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

5.  C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.

Authors:  Jean Kwun; Stuart J Knechtle; Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Miriam Manook; Janghoon Yoon; Mingqing Song; John S Yi; Sanjay Khandelwal; Gowthami M Arepally; Alton B Farris; Edimara S Reis; John D Lambris
Journal:  Nat Commun       Date:  2021-09-15       Impact factor: 17.694

6.  Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.

Authors:  Jan-Michael Abicht; Ioannis Kourtzelis; Bruno Reichart; Sophia Koutsogiannaki; Alexandra Primikyri; John D Lambris; Triantafyllos Chavakis; Lesca Holdt; Alexander Kind; Sonja Guethoff; Tanja Mayr
Journal:  Xenotransplantation       Date:  2016-09-27       Impact factor: 3.907

Review 7.  Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.

Authors:  D C Mastellos; D Ricklin; E Hajishengallis; G Hajishengallis; J D Lambris
Journal:  Mol Oral Microbiol       Date:  2015-10-07       Impact factor: 3.563

8.  Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation.

Authors:  Ioannis Kourtzelis; Klara Kotlabova; Jong-Hyung Lim; Ioannis Mitroulis; Anaisa Ferreira; Lan-Sun Chen; Bettina Gercken; Anja Steffen; Elisabeth Kemter; Anne Klotzsche-von Ameln; Claudia Waskow; Kavita Hosur; Antonios Chatzigeorgiou; Barbara Ludwig; Eckhard Wolf; George Hajishengallis; Triantafyllos Chavakis
Journal:  Thromb Haemost       Date:  2015-12-17       Impact factor: 5.249

9.  Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.

Authors:  Junxiang Wang; Lu Wang; Ying Xiang; Daniel Ricklin; John D Lambris; Gang Chen
Journal:  Clin Immunol       Date:  2015-11-06       Impact factor: 3.969

Review 10.  The Innate Cellular Immune Response in Xenotransplantation.

Authors:  Akira Maeda; Shuhei Kogata; Chiyoshi Toyama; Pei-Chi Lo; Chizu Okamatsu; Riho Yamamoto; Kazunori Masahata; Masafumi Kamiyama; Hiroshi Eguchi; Masahito Watanabe; Hiroshi Nagashima; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.